Company Management_METiS TechBio

Dr. Tsai-Ta Lai (賴才達), aged 36, is our Co-founder, chairman of the Board and a Director of our Company. He has been the chief executive officer of our Company since February 2020 . He was redesignated as our executive Director in August 2025 . He is responsible for the overall management of business strategies, R&D, operation and financing of our Group. Dr. Lai also serves as a director in certain of our subsidiaries of our Company including Beijing Jitai, Shanghai Jitai, Suzhou Jitai, Shanghai Metis, Metis HK, Metis Australia, Metis Therapeutics.

Dr. Lai has extensive work experience in the technology industry and consulting industry. Prior to joining our Group, Dr. Lai served as a chief technology officer of AquaFresco Inc. from June 2016 to June 2017, where he was primarily responsible for the technology development of the company. Dr. Lai served as an associate of McKinsey & Company from July 2017 to July 2019, where he was primarily responsible for providing strategic advisory services. Dr. Lai also served as the head of science and technology strategy and enterprise development (part-time) of the Boston Branch of XtalPi Holdings Limited (深圳晶泰科技有限公司) (HKEX: 2228), where he was primarily responsible for providing strategic advisory services.

Dr. Lai received his bachelor’s degree in chemical engineering from Taiwan University (臺灣大學) in June 2011 . He received his master’s degree and doctorate degree in chemical engineering from Massachusetts Institute of Technology in the United States in June 2014 and June 2016, respectively.

Dr. Hongming Chen, aged 54, is our Co-founder and a Director of our Company. She has been the Chief Research and Development Officer of our Company since December 2021 . She was redesignated as our executive Director in August 2025 . Dr. Chen is primarily responsible for overseeing the R&D activities of our Group. Dr. Chen also serves as a Director and President of Metis Therapeutics, a subsidiary of our Company.

Dr. Chen has approximately 29 years of working and management experience in the pharmaceutical/biotech industry. She once served in Merck & Co. (NYSE: MRK) . From 1997 to 2000, Dr. Chen was a scientist of formulation research and development at AstraZeneca R&D Boston, where she was primarily responsible for developing new formulations and delivery vehicles for recombinant H. pylori proteins for oral vaccination. Dr. Chen was a senior scientist, associate director, and director at Transform Pharmaceuticals from 2000 to 2009, where she was involved in building company core technology platforms, designing novel formulations using the technology platforms, working with strategic partners, optimizing drug formulations and developing proprietary drug products. She also served as the vice president of research, executive vice president of research, and chief scientific officer at Kala Pharmaceuticals, Inc. (NASDAQ: KALA) from 2010 to 2021, where she was primarily responsible for all research and development, building company core technology platforms and intellectual properties, working with strategic partners, and developing proprietary drug products. Dr. Chen is a member of the College of Fellows, American Institute for Medical and Biological Engineering, a member of the National Academy of Engineering, and a member of the College of Fellows, Controlled Release Society.

Dr. Chen received her bachelor’s degree in chemical engineering from the University of Texas, Austin in the United States in 1992 . She received her master’s degree in chemical engineering from Massachusetts Institute of Technology in the United States in 1995, and her doctorate degree in chemical engineering from Massachusetts Institute of Technology in the United States in 1997 .

Dr. Wenshou Wang (王文首), aged 45, is our Co-founder and a director. He has been the chief operating officer of our Company since February 2020 . He was redesignated as our executive Director in August 2025 . Dr. Wang is primarily responsible for overseeing the overall management and business operation of our Group. Dr. Wang also serves as a manager, director and legal representative at Beijing Susida and Hangzhou Metis Life Science.

Prior to joining our Group, Dr. Wang worked as a post-doctoral fellow in the University of Southern Mississippi from January 2007 and as a post-doctoral fellow in the University of Minnesota from July 2010 to June 2012, where he was primarily responsible for research. Dr. Wang also worked as a research scientist in Massachusetts Institute of Technology from November 2012 to June 2017, where he was primarily responsible for scientific research. Dr. Wang then worked as the Co-founder and chief materials scientist in Inkbit Corporation from September 2016 to May 2019, where he was primarily responsible for scientific research. Dr. Wang worked as the senior scientist in XtalPi from May 2019 to February 2020, which has affiliated relation with us as a shareholder of our Company, where he was primarily responsible for scientific research.

Dr. Wang received his bachelor’s degree in chemistry from Henan University (河南大學) in the PRC in July 2001 . Dr. Wang received his master’s degree in polymer chemistry and physics from Chinese Academy of Sciences (中國科學院) in the PRC in March 2007 .

Mr. Hantao Huang (黃瀚濤), aged 30, joined the Group on October 26, 2023 as a non-executive Director. He is primarily responsible for providing professional advice, opinion and guidance to the Board.

Mr. Huang serves as a vice president in CICC Capital Management Co., Ltd. (“CICC Capital”) since January 2023 where he is primarily responsible for private equity fund management, including leading private equity investment projects, fund formation and fundraising with a primary focus on the medical and healthcare industry. Mr. Huang joined CICC Capital in September 2018 as analyst and was promoted to his current position in January 2023 .

Mr. Huang received his bachelor’s degree of science in business and finance from New York University in May 2017 . He also received the Certification of Fund Practice Qualification (基金從業資格證書) from the Asset Management Association of China (中國證券投資基金業協會) in March 2023 .

Ms. Yuan Gong (公元), aged 36, joined the Group on August 1, 2023 as a non-executive Director. She is primarily responsible for providing professional advice, opinion and guidance to the Board.

Ms. Gong joined HSG in September 2019, and currently serves as a partner, where she is primarily responsible for venture capital investment. From September 2012 to September 2019, she served as a venture investor at China Growth Capital, an assistant manager at Deloitte and an associate at PricewaterhouseCoopers (“PwC”), where she was primarily involved in auditing.

Ms. Gong received her Bachelor’s degree in science from Birmingham-Southern College in the US in February 2012 .

Mr. Frank Yee Chon Lyn (林怡仲), aged 66, was appointed as an independent non-executive Director with effect from the Listing Date. Mr. Lyn is primarily responsible for providing independent advice on issues relating to corporate governance, audit and the remuneration and assessment of our Directors and senior management.

Mr. Lyn served as a partner at PricewaterhouseCoopers (“PwC”) from 1993 to 2019 and held multiple senior positions at PwC China & Hong Kong, including markets leader, member of management board, corporate finance leader and Hong Kong senior partner. Mr. Lyn served as an independent non-executive director and the chairman of the audit committee at Mox Bank Limited since July 2020 . Mr. Lyn also served as an independent non-executive director and the chairman of the audit committee of Standard Chartered Bank (China) Ltd. since October 2020 and November 2020, respectively. Mr. Lyn worked as an independent non-executive director and the chairman of the audit committee at SenseTime Group Inc. since December 2021 . Mr. Lyn has been a member of the Hong Kong Institute of Certified Public Accountants (HKICPA) since October 1989 and the Institute of Chartered Accountants in England and Wales (ICAEW) since July 1988 . Mr. Lyn served at The Community Chest (香港公益金) as a director from June 2015 to June 2021 and as a treasurer during the financial years between 2015/2016 to 2019/2020 . Mr. Lyn was also a member of the Chinese People’s Political Consultative Committee of the Guangxi Zhuang Autonomous Region (中國人民政治協商會議廣西壯族自治區委員會) from 2000 to 2018 .

Mr. Lyn received his bachelor’s degree in accounting and finance from Nottingham Trent University (Trent Polytechnic) in the United Kingdom in July 1983 .

Dr. Jin Li (李晉), aged 45, was appointed as an independent non-executive Director with effect from the Listing Date. Dr. Li is primarily responsible for providing independent advice on issues relating to corporate governance, audit and the remuneration and assessment of our Directors and senior management.

From July 2008, Dr. Li worked as an assistant professor of strategy in Kellogg School of Management at Northwestern University. Dr. Li worked as an associate professor of Managerial Economics and Strategy (with tenure) at London School of Economics from September 2017 to July 2018. Dr. Li has worked as an affiliate at Center for the Study of Industrial Organization at Northwestern University. Dr. Li also worked as a visiting scholar in the Bank of Finland Institute for Economies in Transition in January 2004, Dr. Li has been serving as the Area Head of Management and Strategy in Faculty of Business and Economics at the University of Hong Kong since July 2018 . He has worked as Zhang Yonghong Professor in Economics and Strategy and Professor of HKIHSS (by courtesy) . He has been serving as director of Centre for AI, Management and Organization since January 2025 . Since November 21, 2025, Dr. Li has been serving as an independent non-executive Director of China New Economy Fund Limited, a company listed on the Stock Exchange (stock code: 0080) .

Dr. Li received his bachelor of arts degree in economics and math (with High Honor) from Wesleyan University in the United States in 2002, and received his bachelor of science degree in applied math (with Honor) from California Institute of Technology in the United States in 2002 . Dr. Li received his doctorate degree in economics from Massachusetts Institute of Technology in the United States in 2007 .

Dr. Peter Edward Lobie, aged 57, was appointed as an independent non-executive Director with effect from the Listing Date. Dr. Lobie is primarily responsible for providing independent advice on issues relating to corporate governance, audit and the remuneration and assessment of our Directors and senior management.

Dr. Lobie works as the professor of Institute of Biopharmaceutical and Health Engineering in Tsinghua Shenzhen International Graduate School at Tsinghua University and the founding scientist in Sinotar Pharmaceuticals Ltd. at present. Dr. Lobie was employed in Karolinska Institute. After that, he worked at at National University of Singapore and held several positions including as the principal investigator and senior scientist in the Institute of Molecular and Cell Biology, the adjunct faculty in Department of Medicine, and was the principal investigator and associate professor in the Institute of Molecular and Cell Biology from 1996, has worked as the associate director and professor in the Liggins Institute from 2005 to 2011 . Dr. Lobie worked as the senior principal investigator in the Cancer Science Institute of Singapore and the professor of Department of Pharmacology at National University of Singapore from 2011 to 2017 . Dr. Lobie has worked as the professor and co-director in the Centre for Precision Medicine and Healthcare in Tsinghua Berkeley Shenzhen Institute at Tsinghua University from 2017 to 2020 . Dr. Lobie is/was an editorial board member of Cambridge Prisms — Precision Medicine, Endocrinology and Molecular Endocrinology, among a number of other international journals and a visiting/guest professor at a number of institutions in China.

Dr. Lobie received his bachelor’s degree in medical science from the University of Queensland in Australia in 1990, and received his bachelor degree in medicine and surgery (with First Class Honours) from the University of Queensland in Australia in 1992 . Dr. Lobie received his doctorate degree in molecular endocrinology from Karolinska Institutet in Sweden in 1994 .